Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
10.1007/s11684-020-0740-6
- Author:
Ping LI
1
;
Ningxin DONG
2
;
Yu ZENG
1
;
Jie LIU
1
;
Xiaochen TANG
1
;
Junbang WANG
1
;
Wenjun ZHANG
1
;
Shiguang YE
1
;
Lili ZHOU
1
;
Alex Hongsheng CHANG
3
;
Aibin LIANG
4
Author Information
1. Department of Hematology, Tongji Hospital of Tongji University School of Medicine, Shanghai, 200065, China.
2. Department of Imaging, Tongji Hospital of Tongji University School of Medicine, Shanghai, 200065, China.
3. Clinical Translational Research Center, Shanghai Pulmonary Hospital of Tongji University School of Medicine, Shanghai, 200433, China. alexhchang@yahoo.com.
4. Department of Hematology, Tongji Hospital of Tongji University School of Medicine, Shanghai, 200065, China. lab7182@tongji.edu.cn.
- Publication Type:Journal Article
- Keywords:
anti-CD19 chimeric antigen receptor T cells;
long-term follow-up;
mantle cell lymphoma;
relapsed or refractory
- MeSH:
Adult;
Aged;
Cell- and Tissue-Based Therapy;
Humans;
Immunotherapy, Adoptive;
Lymphoma, Mantle-Cell/therapy*;
Neoplasm Recurrence, Local;
Receptors, Chimeric Antigen
- From:
Frontiers of Medicine
2020;14(6):811-815
- CountryChina
- Language:English
-
Abstract:
Mantle cell lymphoma (MCL) is a distinct histological type of B-cell lymphoma with a poor prognosis. Several agents, such as proteasome inhibitors, immunomodulatory drugs, and inhibitors of B cell lymphoma-2 and Bruton's tyrosine kinase have shown efficacy for relapsed or refractory (r/r) MCL but often have short-term responses. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-Hodgkin's lymphoma. However, long-term safety and tolerability associated with CAR T-cell therapy are not defined well, especially in MCL. In this report, we described a 70-year-old patient with r/r MCL with 48-month duration of follow-up who achieved long-term remission after CAR T-cell therapy. CAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient. This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL, who are generally elderly and have comorbid conditions.
